During a press confernece at the 2013 ASH Annual Meeting, Dr Michael Kalos presents data on an overview of patient response in a clinical research program evaluating treatment of paediatric and adult leukaemia patients with experimental CAR genetically engineered T cells. A series of treatment cohorts were included in the analysis, including paediatric and adult patients with high-risk, treatment-resistant acute lymphocytic leukaemia and adult patients with advanced relapsed and/or treatment-resistant chronic lymphocytic leukaemia.
Read our ASH 2013 conference report for free.